FDA approval: Nintedanib

AI Summary

The FDA approved an abbreviated new drug application (ANDA) for a generic nintedanib esylate formulation (100 mg and 150 mg capsules) by Apotex on 2 April 2026. This is a regulatory action confirming bioequivalence and manufacturing standards; it does not provide clinical trial data, efficacy evidence, or safety outcomes.

Plain-language summary

FDA approval of a generic nintedanib formulation; does not contain clinical efficacy data and represents a regulatory action, not evidence of clinical benefit.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval permits marketing of a generic nintedanib product; clinicians and patients may have access to a lower-cost alternative to branded nintedanib for its indicated uses. Clinical efficacy and safety are those of the reference product and are not re-evaluated in this ANDA approval.

Caveats

• This record contains no clinical trial data, efficacy results, or safety outcomes.
• The approval is based on bioequivalence to the reference product, not de novo clinical evidence.
• Indication, dosing, contraindications, and adverse event profile are those of the approved reference drug and are not detailed in this regulatory record.
• No comparator, study design, sample size, or patient population data are provided.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.